Immunotherapeutics for Autoimmune Encephalopathies and Dementias

被引:0
|
作者
Andrew McKeon
机构
[1] Mayo Clinic,College of Medicine
来源
关键词
Autoimmune; Autoimmune encephalopathies; Immunotherapeutics; Encephalopathy; Dementia; Paraneoplastic, Immunotherapy; Steroids; Plasma exchange; Intravenous immune globulin; IVIg; Rituximab; Cyclophosphamide; Azathioprine; Mycophenolate mofetil;
D O I
暂无
中图分类号
学科分类号
摘要
The timely implementation of immunotherapy is key to successful treatment of autoimmune encephalopathies or dementias (from here on will be referred to as autoimmune encephalopathies). There are different levels of diagnostic certainty which should guide the immunological treatment of autoimmune encephalopathies. There is a high level of diagnostic certainty for patients who have classic limbic encephalitis and have a neural antibody detected in serum or CSF (such as potassium channel complex antibody). For these patients, initiating high-dose corticosteroids or IVIg is indicated, with plasma exchange, rituximab or cyclophosphamide used as second-line therapy if first-line therapy proves only partially beneficial. There is a lower level of diagnostic certainty in patients with non-limbic atypical phenotypes (though rapidly progressive) when no neural antibody is detected in serum and CSF. A trial of corticosteroids or IVIg (or both sequentially) may be undertaken in these patients, but if no objective improvements occur, further immunotherapy is unlikely to be beneficial. Antiepileptic treatment also plays a critical role in those who have seizures as well as cognitive symptoms. Evaluation for and treatment of any underlying cancer is another component for those patients with a paraneoplastic cause of encephalitis. An individualized maintenance regimen needs to be designed for patients who do improve with immunotherapy. Individual factors that need to be considered when formulating a program of maintenance treatment include disease severity, antibody specificity and proclivity for disease relapse. Azathioprine and mycophenolate mofetil are frequently used for the purpose of remission maintenance, and should permit gradual withdrawal of steroids, IVIg or more toxic immunosuppressants. The duration of maintenance therapy is uncertain, but this author typically recommends 3–5 years of relapse-free maintenance treatment before discontinuing immunotherapy altogether.
引用
收藏
页码:723 / 737
页数:14
相关论文
共 50 条
  • [21] Behavioral Neurology of Multiple Sclerosis and Autoimmune Encephalopathies
    Moghadasi, Abdorreza Naser
    Pourmand, Shadi
    Sharifian, Maryam
    Minagar, Alireza
    Sahraian, Mohammad Ali
    NEUROLOGIC CLINICS, 2016, 34 (01) : 17 - +
  • [22] MRI of Toxic, Metabolic, and Autoimmune Encephalopathies: A Review
    Gavito-Higuera, Jose
    Mullins, Carola
    Gutierrez-Villalobos, Lisa Ivette
    Sandoval, Hugo
    Shewchuk, Jason
    Ramos-Duran, Luis
    APPLIED RADIOLOGY, 2020, 49 (01) : 10 - 19
  • [23] DEMENTIAS, NEURODEGENERATION, AND VIRAL MECHANISMS OF DISEASE FROM THE PERSPECTIVE OF HUMAN TRANSMISSIBLE ENCEPHALOPATHIES
    MANUELIDIS, L
    SLOW INFECTIONS OF THE CENTRAL NERVOUS SYSTEM: THE LEGACY OF DR BJORN SIGURDSSON, 1994, 724 : 259 - 281
  • [24] Paediatric autoimmune encephalopathies: a lot done, more to do
    McKeon, Andrew
    Lennon, Vanda A.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (07): : 709 - 709
  • [25] NEUROPSYCHIATRIC PRESENTATIONS OF AUTOIMMUNE ENCEPHALOPATHIES: A CLINICAL CASE SERIES
    Namerow, Lisa B.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (10): : S34 - S34
  • [26] Brain FDG-PET in assessment of autoimmune encephalopathies
    Singhal, Tarun
    Bhattacharyya, Shamik
    Klein, Joshua
    Vodopivec, Ivana
    Wong, Janice
    Lyons, Jennifer
    NEUROLOGY, 2018, 90
  • [27] Immunotherapeutics in Pediatric Autoimmune Central Nervous System Disease: Agents and Mechanisms
    Nosadini, Margherita
    Sartori, Stefano
    Sharma, Suvasini
    Dale, Russell C.
    SEMINARS IN PEDIATRIC NEUROLOGY, 2017, 24 (03) : 214 - 228
  • [28] Autoimmune encephalopathies Expanding spectrum of GABAB receptor antibody disorders
    Carter, Jonathan
    Honnorat, Jerome
    NEUROLOGY, 2013, 81 (17) : 1482 - 1483
  • [29] PEDIATRIC AUTOIMMUNE ENCEPHALOPATHIES: WHAT SHOULD A CHILD PSYCHIATRIST KNOW?
    Namerow, Lisa B.
    Mooneyham, GenaLynne C.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (10): : S33 - S33
  • [30] Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression
    Banks, Samantha A.
    Sechi, Elia
    Flanagan, Eoin P.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14